Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naproxen + aspirin refers to the **concurrent use of naproxen and aspirin**, both of which are nonsteroidal anti-inflammatory drugs (NSAIDs). Naproxen acts as a reversible inhibitor of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which leads to reduced inflammation, pain, and fever. Aspirin is an irreversible inhibitor of cyclooxygenase (mainly COX-1 at low doses), inhibiting thromboxane A2 production in platelets, thereby reducing platelet aggregation and providing cardioprotection. When used together, these drugs can provide enhanced anti-inflammatory and analgesic effects, but they also significantly increase the risk of gastrointestinal toxicity and bleeding. Importantly, naproxen can interfere with the antiplatelet effect of aspirin, potentially undermining the cardiovascular protective benefit of aspirin. This combination is not available as a fixed-dose medication but refers to simultaneous administration by prescription or self-medication[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on naproxen + aspirin.